Researchers used the American Academy of Ophthalmology's IRIS database to quantify the risk of endophthalmitis — inflammation of intraocular fluids — after injections with anti-VEGF drugs. They found that post-injection endophthalmitis occurs, on average, once every 3,500 injections.
A study taking advantage of the world’s largest patient specialty patient registry shows that post injection endophthalmitis (PIE) is a rare occurrence despite the growing number of patients being treated with injections of anti-vascular endothelial growth factor (VEGF) as a treatment of retinal conditions such as wet age-related macular degeneration and diabetic macular edema.
The research, presented Saturday at the American Society of Retina Specialists (ASRS) annual scientific meeting in Seattle, showed that smoking is a risk factor and that treating PIE with vitrectomy did not improve outcomes and may, in fact, worsen them.
Alia Durrani, M.D., of the Retina Institute of St. Louis, found that post-injection endophthalmitis (PIE) is a rare occurence but it does occur. Smoking appears to be a risk factor.
Alia Durrani, M.D., of the Retina Institute of St. Louis, said the American Academy of Ophthalmology's Intelligent Research in Sight (IRIS) registry, with its data comprising 440 million patient visits and participation of approximately three-quarters of the practicing ophthalmologists in the United States, is well suited for investigating relatively rare events such as PIE.
Sifting through IRIS data from 2014 through 2020, Durrani and her colleagues 6,109 cases of PIE out of 20.1 million injections, which works out to an incidence of .0286%, or 1 in every 3,500 injections. Of the PIE cases, 738 eyes and 711 patients had bilateral injections, and there were 27 cases of bilateral PIE. The diagnosis was made, on average, four days after the injection. Speedy diagnosis appears to be important:Durrani reported that each day between initial injection of the anti-VEGF agent and diagnosis of endophthalmitis was associated with decreased visual acuity as measured on a Snellen test.
Bilateral, same-day injections did not increase the risk of PIE, Durrani reported, and the researchers did not find any significant association with region, race or insurance carrier. They did, though, find a slightly higher risk among current and past smokers.
However, the research findings may sow questions about the treatment of PIE, because compared with management with intravitreal injection of antibiotics alone, at one year eyes that treated vitrectomy had loss of visual acuity, Durrani said.
It Flopped on Primary Endpoint, But Succeeded on Visual Acuity | ASRS 2023
July 31st 2023AXNOO7, an investigational agent for geographic atrophy, did not affect geographic atrophy lesions but showed positive effects of tests of visual acuity. A novel, neuroprotective mechanism of action may be why.
Read More
When a Biosimilar Might Increase Not Decrease Costs | Ravi Parikh, M.D., M.P.H., ASRS 2023
July 30th 2023The approval of an ophthalmic bevacizumab biosimilar might mean the end of low-cost, repackaged Avastin as an anti-VEGF treatment for retinal diseases, with the unintended consequence of adding $457 million to Medicare B spending.
Read More
Eylea Biosimilar Produces Favorable Results in a Switching Study | ASRS 2023
July 30th 2023Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.
Read More
The Long and Short (Interval Switch) of the PULSAR Trial | ASRS 2023
July 29th 2023About 20% of patients in the trial of a high-dose, longer-interval regimen of Eylea (aflibercept )switched to shorter intervals, according to data presented today at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle. Researchers didn't find any clues as to why in their baseline characteristics.
Read More
Geographic Atrophy Presents Significant Burden to Patients and Caregivers | ASRS 2023
July 29th 2023Patients with geographic atrophy and their caregivers would benefit from support and accommodations related to managing daily life activities and social activities, as well as their mental health, Sophie J. Bakri, M.D., said during her presentation
Read More